Exact Mass: 534.2594

Exact Mass Matches: 534.2594

Found 62 metabolites which its exact mass value is equals to given mass value 534.2594, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-3-(acetyloxy)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}propoxy]phosphonic acid

C25H43O10P (534.2594)


PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)

[(2R)-2-(acetyloxy)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}propoxy]phosphonic acid

C25H43O10P (534.2594)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Ser Arg Ala Val Cys

Ser Arg Ala Val Cys

C20H38N8O7S (534.2584)


   

Cys Glu Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carboxybutanamido]hexanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Cys Glu Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carboxybutanamido]-5-carbamimidamidopentanamido]hexanoic acid

C20H38N8O7S (534.2584)


   

Cys Lys Glu Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-4-carboxybutanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Cys Lys Arg Glu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2R)-2-amino-3-sulfanylpropanamido]hexanamido]-5-carbamimidamidopentanamido]pentanedioic acid

C20H38N8O7S (534.2584)


   

Cys Arg Glu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]-4-carboxybutanamido]hexanoic acid

C20H38N8O7S (534.2584)


   

Cys Arg Lys Glu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]hexanamido]pentanedioic acid

C20H38N8O7S (534.2584)


   

Glu Cys Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2R)-2-[(2S)-2-amino-4-carboxybutanamido]-3-sulfanylpropanamido]hexanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Glu Cys Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-4-carboxybutanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanamido]hexanoic acid

C20H38N8O7S (534.2584)


   

Glu Lys Cys Arg

(2S)-2-[(2R)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-carboxybutanamido]hexanamido]-3-sulfanylpropanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Glu Lys Arg Cys

(4S)-4-amino-4-{[(1S)-5-amino-1-{[(1S)-4-carbamimidamido-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}butyl]carbamoyl}pentyl]carbamoyl}butanoic acid

C20H38N8O7S (534.2584)


   

Glu Arg Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]hexanoic acid

C20H38N8O7S (534.2584)


   

Glu Arg Lys Cys

(4S)-4-amino-4-{[(1S)-1-{[(1S)-5-amino-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}butanoic acid

C20H38N8O7S (534.2584)


   

Lys Cys Glu Arg

(4S)-4-{[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl}-4-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]butanoic acid

C20H38N8O7S (534.2584)


   

Lys Cys Arg Glu

(2S)-2-[(2S)-5-carbamimidamido-2-[(2R)-2-[(2S)-2,6-diaminohexanamido]-3-sulfanylpropanamido]pentanamido]pentanedioic acid

C20H38N8O7S (534.2584)


   

Lys Glu Cys Arg

(4S)-4-{[(1R)-1-{[(1S)-4-carbamimidamido-1-carboxybutyl]carbamoyl}-2-sulfanylethyl]carbamoyl}-4-[(2S)-2,6-diaminohexanamido]butanoic acid

C20H38N8O7S (534.2584)


   

Lys Glu Arg Cys

(4S)-4-{[(1S)-4-carbamimidamido-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}butyl]carbamoyl}-4-[(2S)-2,6-diaminohexanamido]butanoic acid

C20H38N8O7S (534.2584)


   

Lys Arg Cys Glu

(2S)-2-[(2R)-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-sulfanylpropanamido]pentanedioic acid

C20H38N8O7S (534.2584)


   

Lys Arg Glu Cys

(4S)-4-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-4-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}butanoic acid

C20H38N8O7S (534.2584)


   

Met Gln Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C20H38N8O7S (534.2584)


   

Met Gln Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Met Arg Gln Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-3-hydroxybutanoic acid

C20H38N8O7S (534.2584)


   

Met Arg Thr Gln

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-carbamoylbutanoic acid

C20H38N8O7S (534.2584)


   

Met Thr Gln Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-hydroxybutanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Met Thr Arg Gln

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanoic acid

C20H38N8O7S (534.2584)


   

Gln Met Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C20H38N8O7S (534.2584)


   

Gln Met Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Gln Arg Met Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanamido]-3-hydroxybutanoic acid

C20H38N8O7S (534.2584)


   

Gln Arg Thr Met

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-(methylsulfanyl)butanoic acid

C20H38N8O7S (534.2584)


   

Gln Thr Met Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-hydroxybutanamido]-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Gln Thr Arg Met

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanoic acid

C20H38N8O7S (534.2584)


   

Arg Cys Glu Lys

(2S)-6-amino-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]-4-carboxybutanamido]hexanoic acid

C20H38N8O7S (534.2584)


   

Arg Cys Lys Glu

(2S)-2-[(2S)-6-amino-2-[(2R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-sulfanylpropanamido]hexanamido]pentanedioic acid

C20H38N8O7S (534.2584)


   

Arg Glu Cys Lys

(2S)-6-amino-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carboxybutanamido]-3-sulfanylpropanamido]hexanoic acid

C20H38N8O7S (534.2584)


   

Arg Glu Lys Cys

(4S)-4-{[(1S)-5-amino-1-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}pentyl]carbamoyl}-4-[(2S)-2-amino-5-carbamimidamidopentanamido]butanoic acid

C20H38N8O7S (534.2584)


   

Arg Lys Cys Glu

(2S)-2-[(2R)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-sulfanylpropanamido]pentanedioic acid

C20H38N8O7S (534.2584)


   

Arg Lys Glu Cys

(4S)-4-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-4-{[(1R)-1-carboxy-2-sulfanylethyl]carbamoyl}butanoic acid

C20H38N8O7S (534.2584)


   

Arg Met Gln Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-3-hydroxybutanoic acid

C20H38N8O7S (534.2584)


   

Arg Met Thr Gln

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanamido]-3-hydroxybutanamido]-4-carbamoylbutanoic acid

C20H38N8O7S (534.2584)


   

Arg Gln Met Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-3-hydroxybutanoic acid

C20H38N8O7S (534.2584)


   

Arg Gln Thr Met

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-3-hydroxybutanamido]-4-(methylsulfanyl)butanoic acid

C20H38N8O7S (534.2584)


   

Arg Thr Met Gln

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanoic acid

C20H38N8O7S (534.2584)


   

Arg Thr Gln Met

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanoic acid

C20H38N8O7S (534.2584)


   

Thr Met Gln Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Thr Met Arg Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanoic acid

C20H38N8O7S (534.2584)


   

Thr Gln Met Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanoic acid

C20H38N8O7S (534.2584)


   

Thr Gln Arg Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-carbamoylbutanamido]-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanoic acid

C20H38N8O7S (534.2584)


   

Thr Arg Met Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanamido]-4-carbamoylbutanoic acid

C20H38N8O7S (534.2584)


   

Thr Arg Gln Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-carbamoylbutanamido]-4-(methylsulfanyl)butanoic acid

C20H38N8O7S (534.2584)


   

SRAVC

Ser-Arg-Ala-Val-Cys

C20H38N8O7S (534.2584)


   

Acetamide, N-[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]-N-[4-[[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]amino]butyl]-

Acetamide, N-[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]-N-[4-[[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]amino]butyl]-

C28H34N6O5 (534.2591)


D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].

   

Macimorelin Acetate

Macimorelin Acetate

C28H34N6O5 (534.2591)


   

PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C25H43O10P (534.2594)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)

C25H43O10P (534.2594)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C25H43O10P (534.2594)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C25H43O10P (534.2594)